EASL Studio Podcast S6 E14: Endohepatology: The endoscopic liver gold rush

EASL Studio Podcast S6 E13: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Studio Podcast S6 E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?

EASL Studio Podcast S6 E10: YI Choice: Citizen science: Societal engagement in hepatology

EASL Studio Podcast S6 E9: Therapy hierarchy in HCC: A new kid on the block

EASL Studio Podcast S6 E8: Is there a role for measuring blood ammonia in patients with cirrhosis?

EASL Studio Podcast S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

EASL Studio Podcast S6 E6: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

EASL Studio Podcast S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

EASL Studio Podcast S6 E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond

EASL Studio Podcast S6 E3: How to stop recurrent bleeding due to small-intestinal angiodysplasia?

EASL Studio Podcast S6 E2: Why do we need HBV functional cure?

EASL Studio Podcast S6 E1: Do we solve MASLD by treating obesity?

EASL Studio Podcast S5 E15: EASL Studio’s holiday reflection: A look back to leap forward

EASL Studio Podcast S5 E14: Hepatic encephalopathy: Underdiagnosed and underestimated

EASL Studio Podcast S5 E13: Basics in decision-making for liver cancer treatment

EASL Studio Podcast S5 E12: PSC and AIH overlap syndrome: does it actually exist?

EASL Studio Podcast S5 E11: The window hypothesis again, or just a closed window?

EASL Studio Podcast S5 E10: Why should diabetologists care about the liver?

EASL Studio Podcast S5 E9: Alcohol and the new nomenclature – A game-changer?